T1	Participants 116 155	advanced head and neck cancer patients.
T2	Participants 498 566	first-line treatment of patients with advanced head and neck cancer.
T3	Participants 587 763	successive patients with unresectable grade I/II head and neck cancer who were not suitable for irradiation treatment (T any N3 or T4 N2C), metastatic or previously irradiated.
T4	Participants 888 939	A total of 170 patients were included in the study.
T5	Participants 3186 3216	head and neck cancer patients.
